戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 kidney cancer (hereditary leiomyomatosis and renal cell cancer).
2 ients with metastatic malignant melanoma and renal cell cancer.
3 ition syndrome hereditary leiomyomatosis and renal cell cancer.
4  and lymphoid malignancies and in metastatic renal cell cancer.
5 ydratase cause hereditary leiomyomatosis and renal cell cancer.
6 romosome 10q deletion in primary bladder and renal cell cancer.
7 lected patients with metastatic melanoma and renal cell cancer.
8 on itself, may contribute to the etiology of renal cell cancer.
9 velopment of an aggressive form of papillary renal cell cancer.
10 t models of metastatic lung, pancreatic, and renal cell cancer.
11  metastatic malignant melanoma or metastatic renal cell cancer.
12 ifferent tumours, such as breast, ovarian or renal cell cancer.
13            Odds ratios were not elevated for renal cell cancer.
14 mas as well as hereditary leiomyomatosis and renal cell cancer.
15 ond-line therapy in patients with metastatic renal cell cancer.
16 st, lung, ovarian, pancreatic, prostate, and renal cell cancer.
17 ts and therefore may also reduce the risk of renal cell cancer.
18 lescence, is associated with reduced risk of renal cell cancer.
19 th melanoma, non-small-cell lung cancer, and renal cell cancer.
20 cence were associated with a reduced risk of renal cell cancer.
21  for human bladder, head and neck, lung, and renal cell cancer.
22 significant activity of PS-341 in metastatic renal cell cancer.
23 e inhibitor PS-341 in patients with stage IV renal cell cancer.
24 myoma syndrome (MCL) and MCL associated with renal cell cancer.
25 cated as risk factors for the development of renal-cell cancer.
26 ith non-small-cell lung cancer, melanoma, or renal-cell cancer.
27 nhibitors approved for treatment of advanced renal-cell cancer.
28 ng non-small-cell lung cancer, melanoma, and renal-cell cancer.
29 ssion of disease in patients with metastatic renal-cell cancer.
30 n 65 of 285 (23%) bladder and 15 of 60 (25%) renal cell cancers.
31 herin-6 expression in a series of 32 primary renal cell cancers.
32 mary head and neck, non-small cell lung, and renal cell cancers.
33 odels and in some patients with melanoma and renal cell cancers.
34 melanoma, 18 with colorectal cancer, 17 with renal-cell cancer, 17 with ovarian cancer, 14 with pancr
35                     Of the 201 patients with renal cell cancer, 18 achieved CRs and 20 PRs, for an ov
36 9 of 52 patients with melanoma, 2 of 17 with renal-cell cancer, 5 of 49 with non-small-cell lung canc
37                       Of the 15 DTCs, 6 were renal cell cancer; 5, lung cancer; 2, lymphoma; 1, neuro
38 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).
39 est that the flavonoid quercetin may prevent renal cell cancer among male smokers.
40 y, further etiologic research is needed into renal cell cancer, an increasingly common form of cancer
41 isk of upper urinary tract cancer, including renal cell cancer and cancers of the renal pelvis or ure
42                        Search terms included renal cell cancer and first-line and were filtered by th
43 udies in untreated patients with melanoma or renal cell cancer and in other rhIL-12-responsive malign
44  mutation in von Hippel-Lindau (VHL) develop renal cell cancers and hypervascular tumors of the brain
45                                          All renal cell cancers and most breast cancers, non-Hodgkin
46 FR) inhibitor under clinical development for renal-cell cancer and other solid tumors.
47 or former smokers had a greater risk of both renal-cell cancer and renal-pelvis cancer than men who w
48 nal stromal tumours, neuroendocrine cancers, renal-cell cancer and sarcoma is associated with longer
49 derlying malignancy (renal cell cancer v non-renal cell cancer) and TKI (sunitinib v sorafenib), but
50 uamous cell cancers, 2 with melanoma, 1 with renal cell cancer, and 1 with adenocarcinoma of the lung
51 substantially lower the overall incidence of renal cell cancer, and 2) intervention measures may have
52 oval for the treatment of advanced melanoma, renal cell cancer, and non-small cell lung cancer.
53 ghths had a 30 to 60 percent greater risk of renal-cell cancer, and men in the highest two eighths ha
54 oliferative diseases, colorectal cancer, and renal cell cancer being the most common.
55 re enrolled into Medicare and diagnosed with renal cell cancer between 1986 and 1999.
56 ed for treatment of patients with metastatic renal-cell cancer, but no validated biomarkers are avail
57 e primary tumors of patients with metastatic renal cell cancer by using cDNA microarrays.
58 de that survival in patients with metastatic renal cell cancer can be correlated with the expression
59  rate among blacks compared with whites with renal cell cancer can be explained largely by the increa
60            After 8.3 years of follow-up, 347 renal cell cancer cases (220 men, 127 women) were identi
61 thors present estimates of the proportion of renal cell cancer cases attributable (or population attr
62                                   Clear cell renal cell cancer (CC-RCC) is a highly chemoresistant tu
63 e and also occur in most sporadic clear cell renal cell cancers (CCRCC).
64 l common malignancies, for example colon and renal cell cancer, code for ubiquitin ligase components.
65                                   Clear-cell renal cell cancer (CRCC) is initiated typically by loss
66                        Analysis included 335 renal cell cancer deaths (123 in women and 212 in men).
67 ts, 21 of 23 with melanoma and 34 of 38 with renal cell cancer developed at least PRs after the first
68 al trials conducted decades ago for advanced renal-cell cancer did not show significant clinical bene
69 open radical nephrectomy for the majority of renal cell cancers due to equivalent oncologic control,
70 d a unique association of MN expression with renal cell cancers, especially those of the clear cell v
71  patient with melanoma, and one patient with renal cell cancer had complete regression of pulmonary m
72 for a relation between physical activity and renal cell cancer has been inconsistent.
73       The value of nephrectomy in metastatic renal-cell cancer has long been debated.
74                          Black patients with renal cell cancer have shorter survival compared with th
75 ase (FH) drive hereditary leiomyomatosis and renal cell cancer (HLRCC) and increase the risk of devel
76                Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disor
77                Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an inherited cancer syndrom
78 mata (MCL) and hereditary leiomyomatosis and renal cell cancer (HLRCC), and recently, FH mutations ha
79 a rare cancer, hereditary leiomyomatosis and renal cell cancer (HLRCC), characterised by benign smoot
80 CUL1), and the hereditary leiomyomatosis and renal cell cancer (HLRCC), implicated FH, a gene on chro
81  FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH caus
82 drome known as hereditary leiomyomatosis and renal cell cancer (HLRCC).
83                Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder chara
84 esponsible for hereditary leiomyomatosis and renal-cell cancer (HLRCC).
85 ar relative survival rates for patients with renal cell cancer improved among whites but not among bl
86 rs examined physical activity in relation to renal cell cancer in a large, prospective US cohort stud
87 ostatin at 10 mg/kg suppressed the growth of renal cell cancer in a nude mouse model.
88 ypertensive medications to the risk of fatal renal cell cancer in a prospective cohort study of 998,9
89  predispose to hereditary leiomyomatosis and renal cell cancer in affected individuals.
90 oking, and hypertension are risk factors for renal cell cancer in both sexes.
91 uting to the rapidly increasing incidence of renal cell cancer in the United States, particularly amo
92 ents who are at increased risk of developing renal cell cancer in their native kidneys.
93 pment of cutaneous and uterine leiomyoma and renal cell cancer in this syndrome.
94                             Men with cancer (renal-cell cancer in 759 and renal-pelvis cancer in 136)
95 independently increase the long-term risk of renal-cell cancer in men.
96                                              Renal cell cancer incidence rates increased steadily bet
97 roscopic retroperitoneal lymphadenectomy for renal cell cancer is safe and allows for adequate stagin
98 itors (SMIs) are commonly used in metastatic renal cell cancer (mRCC) patients; patients often develo
99                               Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group o
100  also known as hereditary leiomyomatosis and renal cell cancer), NRF2 activation is a direct conseque
101 rapy, such as pancreatic, hepatocellular, or renal-cell cancer or melanoma.
102 nts with a prior diagnosis of breast cancer, renal cell cancer, or leukemia underwent whole-body PET/
103  higher blood pressures and a higher risk of renal-cell cancer (P for trend, <0.001 for diastolic pre
104 n of the Fas(CD95)-R expression on PBLs from renal cell cancer patients compared with normal healthy
105 observed at or above the MTD in melanoma and renal cell cancer patients.
106 tched peripheral blood lymphocytes (PBLs) of renal cell cancer patients.
107             Patients with advanced papillary renal cell cancer (pRCC) have poor survival after system
108                             For melanoma and renal cell cancer, prognostic factors were Karnofsky per
109 se-escalation study, which was followed by a renal cell cancer (RCC) dose-expansion cohort.
110 ed LN in patients with advanced melanoma and renal cell cancer (RCC) for therapy.
111   Genome-wide association studies (GWASs) of renal cell cancer (RCC) have identified four susceptibil
112                                              Renal cell cancer (RCC) incidence has increased in the U
113                                              Renal cell cancer (RCC) is a heterogeneous disease consi
114 overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of tw
115          Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease con
116                       Patients with stage IV renal cell cancer (RCC) were vaccinated with irradiated
117 we also performed a comparison analysis with renal cell cancer (RCC)) studies that evaluated sorafeni
118 ast cancer, prostate cancer, bladder cancer, renal cell cancer (RCC), and malignant melanoma data in
119 ile of genes silenced by hypermethylation in renal cell cancer (RCC), we did an expression microarray
120  it is named and the development of sporadic renal cell cancer (RCC).
121 ons between reproductive factors and risk of renal cell cancer (RCC).
122  first- or second-line therapy in metastatic renal cell cancer (RCC).
123 anscription factors and tumor suppressors in renal cell cancer (RCC).
124 pared the transcriptional profile of primary renal cell cancers (RCCs) with that of normal kidney tis
125 s mDC of patients with advanced melanoma and renal cell cancer reduced the activation and Th1 cytokin
126 nce for aldosterone serving a causal role in renal cell cancer regulation via its GPER receptor; thus
127 a (relative risk 3.10, 95% CI 1.26-7.63) and renal cell cancer (relative risk 5.67, 0.66-48.42).
128 o 22+ months) and one of three patients with renal cell cancer (response duration, 14 months).
129 tivariate Cox regression models adjusted for renal cell cancer risk factors, the authors observed tha
130                                              Renal cell cancer risk increased with increasing body ma
131 size, lifestyle, and medical conditions with renal cell cancer risk was examined among 161,126 Hawaii
132             Hypertension was associated with renal cell cancer (RR-men = 1.42, 95% CI: 1.07, 1.87; RR
133                                       All 12 renal cell cancers showed a low binding of sst2 with the
134 nger survival among patients with metastatic renal-cell cancer than does interferon therapy alone.
135 on-free survival in patients with metastatic renal cell cancer; the phase II data were confirmed in a
136 ith non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not ap
137 ccumulation in hereditary leiomyomatosis and renal cell cancer tumors is thought to result from fumar
138 so stratified for the underlying malignancy (renal cell cancer v non-renal cell cancer) and TKI (suni
139     A population-based case-control study of renal cell cancer was conducted in Minnesota between 198
140  PET/CT imaging of 10 subjects with stage IV renal cell cancer was performed after intravenous admini
141  effects of preclinical disease, the risk of renal-cell cancer was still consistently higher in men w
142 w-up (through December 2003), 1,238 cases of renal cell cancer were ascertained.
143           Patients with stage IV melanoma or renal cell cancer were treated every 3 wk with an anti-C
144 f immunotherapeutic approaches in metastatic renal cell cancer, which have produced a consistent demo
145   Most patients with metastatic melanoma and renal cell cancer who achieved PRs or CRs to intravenous
146 were assessed in 39 patients with metastatic renal cell cancer who received a TKI.
147  patients with either metastatic melanoma or renal cell cancer who were treated with high-dose bolus
148 ates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those r
149 e randomly assigned patients with metastatic renal-cell cancer who were acceptable candidates for nep
150                                              Renal cell cancer with nodal metastases is an independen
151                      Whereas the majority of renal cell cancers with histology-associated poor progno

 
Page Top